期刊文献+

肿瘤抗原MAGE-12新的HLA-A2限制性细胞毒性T细胞表位的预测 被引量:3

Prediction of a novel HLA-A2-restriced CTL epitope derived from the tumor antige n MAGE-12
暂未订购
导出
摘要 目的 预测黑色素瘤抗原MAGE-12的HLA-A2限制性CTL表位。方法 采用SYFPEITHI超基序远程预测系统与量化基序多项式法、延展基序联合应用,筛选MAGE-12抗原HLA-A0201限制性CTL表位。结果 共预测出5个MAGE-12抗原HLA-A2限制性CTL表位。结论 超基序法与量化基序,延展基序联合应用可以提高预测效率,为实验方法探索MAGE-12的表位提供有用线索。 Objective To predict the HLA-A2-restricte d CTL epitopes from melanoma antigen MAGE-12. Methods HLA- A2-restricted CTL epitope of MAGE-12 was predicted by peptide supermotif predict ion combined, quantitative motif and extended motifs. Results Five HLA-A2-restricted CTL epitope candidates derived from the tumor antig en MAGE-12 were selected. Conclusion The combination of supermotif, quantitative motif and extended motifs can improve the prediction ef ficiency. The predicted epitopes provided useful hints to probe epitopes in MAGE -12 by experiments.
出处 《现代肿瘤医学》 CAS 2005年第2期149-151,共3页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(30271464)
关键词 肿瘤抗原 MAGE-12 细胞毒性T淋巴细胞表位 预测 tumor-antigen MAGE-12 cytotoxic T lymphoc yte epitope prediction.
  • 相关文献

参考文献3

二级参考文献18

  • 1Boon T, Van Pel A. T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by trascription and translation of short subgenic regions. A hypothesis. Immuno Genetics,1989, 29:75-79.
  • 2Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3A1 peptide-plused mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage Ⅳ melanoma. J Exp Med, 1999, 190:1669-1678.
  • 3Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol, 2002, 38:158-164.
  • 4Rammensee HG, Bachmann J, Emmerich NPN, et al. SYFPEITHI:database for MHC ligands and peptide motifs. Immunogenetics,1999,50:213-219.
  • 5Gulukota K, Sidney J, Sette A, et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol, 1997, 267:1258-1267.
  • 6Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA- A*0201 epitope identified by mass spectrometry. Cancer Res, 2001,61: 4072-4077.
  • 7Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol, 1998, 59:1-14.
  • 8van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol, 1994, 24:3038-3043.
  • 9Falk K, Rotzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature, 1991,351: 290-296.
  • 10Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol, 1994, 152:163-175.

共引文献20

同被引文献16

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部